君实生物JS212临床试验申请获得FDA批准

Core Viewpoint - Junshi Biosciences (stock code: 688180) announced that its clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the U.S. Food and Drug Administration (FDA) [1] Group 1 - JS212 is a recombinant humanized bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) [1] - The primary indication for JS212 is the treatment of advanced malignant solid tumors [1]